Company
Munich, OS
Every investor coverage indicates participated in a round ITM Isotope Technologies Munich raised.
The transaction that ended ITM Isotope Technologies Munich's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Telix Pharmaceuticals | Merger | 21 Sep 2026 | ≤$3.3b | Biotech Dispatch, Business News Australia |
Companies ITM Isotope Technologies Munich acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Andrew Cavey | CEO | Biotech Dispatch, Business News Australia |
Stories naming ITM Isotope Technologies Munich. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne's Telix Pharmaceuticals will merge with German radioisotope maker ITM in a deal worth as much as $3.3 billion, keeping about 76 per cent ownership with existing Telix shareholders once completed.
Also Biotech Dispatch
Australian-listed Telix is buying German radioisotope supplier ITM in a $1.65 billion deal with contingent milestone payments, creating an end-to-end radiopharmaceutical business.